The Week in Review: September 15 – September 22, 2017

Friday, September 22, 2017 News Recap: Access to Treatment: This was a good week in terms of treatment access (but not, unfortunately, in terms of weather or seismic activity: How very, very sad).  Imagine being sick or on treatment in one of these stricken areas! In Canada Epclusa was approved for use in persons co-infected with HIV. This is very good news. Gilead Receives Approval in Canada for Expanded Indication of EPCLUSA® (Sofosbuvir/Velpat...

Malaysia Allows Generics for Gilead’s Hepatitis C Drug for Which India Issued Patent

The Malaysian government has approved a government-use compulsory license which would allow the import of generic versions of Gilead’s patented hepatitis C drug, Sovaldi. The decision was made in August but has become public this week. On September 14, the Malaysian cabinet approved for this license. The move will make generic and cheaper versions of the same drug, which has been sold globally at $1000 per pill. The low-cost versions will now be available

The Week in Review: July 14 – July 21, 2017

Friday, July 21, 2017 News Recap 1) Vosevi Approved in US – Under Review in Canada Vosevi has just been approved in the USA to treat adults with chronic HCV genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis. Vosevi is a fixed-dose, combination tablet containing sofosbuvir, velpatasvir and a new drug, voxilaprevir. Vosevi is the first treatment approved for patients who have been previously treated with DAAs and failed treatment....

500,000 Malaysian have hepatitis C — they just don’t know it yet

KUALA LUMPUR — It is estimated that about 500,000 Malaysians have Hepatitis C, but most of them are unaware of their infection, said the country’s Health Minister Dr S Subramaniam. Calling it a major challenge in the medical field, he said Hepatitis C incidence rates saw an increase from 3.71 per cent in 2009 to 8.57 per cent in 2016. "However, we must also be cognizant of the fact that the figures obtained from the Health Ministry may be an underestim

Hepatitis C: New hope for patients

A non-profit organisation is making headway in its initiative to develop drugs for neglected diseases to benefit those who can’t afford them. New Sunday Times speaks to two medical practitioners who are working towards making affordable Hepatitis C treatment available to local hospitals. OF the estimated 150 million people infected with chronic Hepatitis C around the world, approximately 75 per cent live in low- to middle-income countries. However, som